Nektar Therapeutics (NKTR)

Nektar Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	215	108	425	2,493	3,050	3,797
Market Cap Growth	28.96%	-74.63%	-82.96%	-18.24%	-19.69%	-33.26%
Enterprise Value	40	-78	51	1,903	2,138	2,881
PE Ratio	-	-0.39	-1.15	-4.76	-6.86	-8.62
PS Ratio	2.39	1.20	4.61	24.47	19.94	33.13
PB Ratio	1.70	0.82	1.16	3.67	2.83	2.70
P/FCF Ratio	-0.91	-0.56	-1.43	-5.83	-9.51	-10.70
P/OCF Ratio	-0.91	-0.56	-1.40	-6.04	-9.73	-11.55
EV/Sales Ratio	0.45	-0.87	0.56	18.67	13.98	25.13
EV/EBITDA Ratio	0.03	0.32	-0.16	-4.12	-5.45	-7.57
EV/EBIT Ratio	0.02	0.31	-0.15	-4.00	-5.26	-7.32
EV/FCF Ratio	0.02	0.41	-0.17	-4.45	-6.67	-8.12
Debt / Equity Ratio	0.90	0.90	0.36	0.21	0.14	0.29
Debt / EBITDA Ratio	-0.79	-0.48	-0.41	-0.31	-0.38	-1.07
Debt / FCF Ratio	-0.61	-0.61	-0.44	-0.33	-0.47	-1.15
Quick Ratio	5.59	5.95	7.49	8.88	9.51	3.85
Current Ratio	6.10	6.45	8.01	9.34	9.83	4.02
Asset Turnover	0.21	0.19	0.11	0.08	0.09	0.06
Interest Coverage	-6.20	-9.90	-11.62	-10.06	-10.96	-8.49
Return on Equity (ROE)	-114.60%	-151.60%	-79.80%	-62.00%	-37.00%	-29.00%
Return on Assets (ROA)	-40.60%	-58.20%	-43.60%	-40.10%	-27.20%	-21.20%
Return on Capital (ROIC)	-68.28%	-106.00%	-75.52%	-54.23%	-34.63%	-24.26%
Earnings Yield	-81.67%	-256.12%	-86.68%	-21.01%	-14.57%	-11.60%
FCF Yield	-87.28%	-178.34%	-69.80%	-17.15%	-10.51%	-9.35%
Buyback Yield / Dilution	-3.11%	-1.53%	-2.09%	-2.64%	-2.05%	2.85%
Total Shareholder Return	-3.11%	-1.53%	-2.09%	-2.64%	-2.05%	2.85%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).